Horizon prepares to dive into chilly IPO market

Horizon Pharma will reportedly make its bid to go public this week in an effort to raise up to $66 million. The company, which develops meds for arthritis and pain, will try and offer 5.5 million shares for between $10 and $12 each. So far this year there has been a rising number of IPOs, but many have been forced to cut their share price as investors steered clear of the kind of high risks associated with biotechnology. Story

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.